Mologen Ag

MOLOGEN is a biopharmaceutical company specializing in the research and clinical development of innovative medical therapies. Our company, formerly listed on the Frankfurt Stock Exchange, was acquired by a group of institutional investors in 2023. Since then, we have been transforming from a biotech to a life science company focused on research, product development and direct B2C sales. Our current USP is a patented technology to extract activated nanovesicles from biological cells that have a diverse and additive effect on drugs, nutritional supplements and cosmetics. We focus on highly effective products for the prevention and treatment of health problems in niche segments such as fertility, ophthalmology, sexual health etc. In addition to our products, we will publish independent medical content in the form of podcasts, seminars and product tests and position our company as a competent partner in the healthcare and life sciences sectors. Our target markets are Europe, Southeast Asia and China.